Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Feb 15;32(2):507-9.
doi: 10.1016/j.pnpbp.2007.10.004. Epub 2007 Oct 13.

Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study

Christina W Slotema  1 , Peter N van Harten, Richard Bruggeman, Hans W Hoek
Affiliations
Comparative Study

Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study

Christina W Slotema et al. Prog Neuropsychopharmacol Biol Psychiatry. .

Abstract

Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.

Methods: In a single blind (raters were blind) study (N=12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).

Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their antipsychotic medication (N=8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.

Conclusion: BTA was well tolerated and showed a non-significant improvement for OTD. A larger double blind study is warranted.

PubMed Disclaimer

Publication types

MeSH terms

Substances